Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial of Cisplatin and Irinotecan (NSC-616348) Versus Cisplatin and Etoposide in Patients With Extensive Stage Small Cell Lung Cancer (E-SCLC)

NCT00045162 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT00045162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00045162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial of Cisplatin and Irinotecan (NSC-616348) Versus Cisplatin and Etoposide in Patients With Extensive Stage Small Cell Lung Cancer (E-SCLC)
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2002
Completion date
December 31, 2009
Enrollment
671 (actual)
Sites
408

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer